Business Context and Reporting Period
Company: Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.)
Filing Type: Form 10-Q
Period Ended: September 30, 2025
Business Overview: The Company is a biopharmaceutical firm developing biomarker-targeted antibody therapies, primarily sirexatamab (DKN-01) for cancer. In November 2025, the Company changed its name and ticker symbol (LPTX to CYPH) to reflect a strategic pivot. While biotech operations continue under a subsidiary, the parent company has initiated a digital asset treasury strategy focused on acquiring Zcash (ZEC).
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,303) | $(18,176) | $(35,381) | $(52,124) |
| Operating Expenses | $3,166 | $17,855 | $35,964 | $53,932 |
| Research & Development | $1,247 | $14,915 | $24,695 | $44,099 |
| Cash and Equivalents (End of Period) | $9,686 | $62,823 | $9,686 | $62,823 |
| Accumulated Deficit | $(502,752) | $(451,940) | $(502,752) | $(451,940) |
Note: The Company has no product revenue. Cash flow from operations was negative $37.3 million for the nine months ended September 30, 2025.
Material Changes vs. Prior Period
- Significant Expense Reduction: Operating expenses decreased by approximately 82% in Q3 2025 compared to Q3 2024 ($3.2M vs $17.9M). This was driven by a 75% workforce reduction in June/July 2025 and the wind-down of clinical trials for sirexatamab and FL-501.
- Restructuring Charges: The Company incurred $4.5 million in restructuring charges during the nine months ended September 30, 2025, primarily for severance and accelerated stock-based compensation. No such charges were recorded in the prior year period.
- Cash Burn: Cash and cash equivalents declined from $47.2 million at year-end 2024 to $9.7 million at September 30, 2025, reflecting a net cash outflow of $37.6 million over the nine-month period.
- Strategic Pivot: The Company shifted from a pure-play biotech model to a hybrid model, retaining biotech R&D in a subsidiary while the parent entity pursues a Zcash treasury strategy.
Guidance, Outlook, and Risks
Subsequent Events & Capital Raise: On October 8, 2025, the Company closed a private placement raising approximately $58.9 million in gross proceeds (net proceeds ~$57.0 million). The transaction included common stock, pre-funded warrants, and common warrants. The Company intends to use a portion of these funds to acquire Zcash (ZEC).
Outlook: Management believes current cash plus proceeds from the October 2025 placement will fund operations for at least 12 months. The Company plans to engage with regulatory authorities regarding the registrational pathway for sirexatamab in the first quarter of 2026.
Key Risks:
- Digital Asset Volatility: The Company's financial results will now be subject to the high volatility of Zcash prices. Unrealized gains/losses on ZEC will be recognized in net income.
- Regulatory Uncertainty: Risks include potential reclassification of ZEC as a security, EU regulations prohibiting privacy-focused assets (effective 2027), and custody risks with third-party providers (Gemini).
- Liquidity: Continued dependence on capital markets for funding; failure to raise additional capital could force further curtailment of operations.
Investor Verification Checklist
- Capital Structure Dilution: Verify the impact of the October 2025 private placement (15.2M shares + 80.8M pre-funded warrants + 72M common warrants) on existing shareholder ownership.
- Zcash Holdings: Confirm the specific amount of ZEC purchased post-quarter-end (reported as 203,775 tokens for ~$50M) and the valuation methodology used under ASU 2023-08.
- Biotech Asset Status: Review the final clinical data for sirexatamab (DeFianCe study) presented at ESMO 2025 and the timeline for regulatory engagement.
- Custody Arrangements: Assess the risks associated with relying on Gemini (an affiliate of the Lead Investor) for the custody and trading of digital assets.
- Going Concern: Evaluate the sufficiency of the $57M net proceeds to sustain the dual strategy (biotech R&D + crypto treasury) beyond the 12-month horizon.